IBEX Technologies Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- IBEX Technologies Inc., now operating as a specialized subsidiary of BBI Solutions OEM Limited, focuses on the development and production of high-purity enzymes for biomedical applications. The company, based in Montreal, Canada, where it was established in 1972, provides its offerings to clients across Canada, the United States, Germany, the United Kingdom, and various international markets. Its core product line encompasses recombinant glycosaminoglycan lyases, featuring enzymes such as Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B. Additionally, IBEX Technologies manufactures collagen ELISAs designed for researching connective tissue synthesis and degradation, alongside a selection of collagen antibodies and diamine oxidase liquid. The company also contributes to osteoarthritis research through its array of arthritis assays. Beyond its product portfolio, IBEX Technologies extends its expertise through various services. These include lyophilization services for fabricating disposable medical device components, custom fermentation, and contract manufacturing solutions for specialized reagents. The company primarily serves manufacturers of medical devices, quality control laboratories, producers of low molecular weight heparin, and academic research institutions. IBEX Technologies Inc.'s shares were delisted from the TSX Venture Exchange following its acquisition by BBI Solutions in April 2024.
Company News
IBEX Limited: AI BPO Could Be The Next Growth Driver
IBEX Limited (IBEX) Q4 2026 Earnings Call Transcript
IBEX Q4 Earnings Call Highlights
IBEX Reports Record Fiscal Year 2026 Financial Results, Introduces Fiscal Year 2027 Guidance
Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate
IBEX Limited to Announce Fourth Quarter and Fiscal Year 2026 Financial Results on September 10, 2026
IBEX Limited Announces $20 Million Share Repurchase Program
IBEX Limited (IBEX) Q3 2026 Earnings Call Transcript
IBEX Limited to Announce Third Quarter 2026 Financial Results on May 6, 2026
IBEX Limited: A Hidden Growth Engine In Healthtech
IBEX Limited (IBEX) Q2 2026 Earnings Call Transcript
IBEX Reports Record Quarterly Revenue and EPS, Raises Fiscal Year Guidance
IBEX Limited to Announce Second Quarter 2026 Financial Results on February 5, 2026
IBEX: A Boring Business That Keeps Beating Expectations
IBEX Limited (IBEX) Q1 2026 Earnings Call Transcript
Critical Survey: IBEX (NASDAQ:IBEX) & Acacia Research (NASDAQ:ACTG)
IBEX Limited to Announce First Quarter 2026 Financial Results on November 6, 2025
IBEX Limited: Strong Earnings, AI Adoption, And More Upside Ahead
IBEX Limited (IBEX) Q4 2025 Earnings Call Transcript
Quiet Performer, Strong Case: IBEX Deserves A Spot In Your Portfolio